Morgan Stanley raised the firm’s price target on Kymera Therapeutics (KYMR) to $73 from $70 and keeps an Overweight rating on the shares. Much of the attention on Kymera’s Q3 earnings call was centered around the upcoming Phase 1b atopic dermatitis readout expected in December, notes the analyst, who says Kymera reiterated confidence in KT-621.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release
- Kymera Therapeutics price target raised to $73 from $64 at Jefferies
- Kymera Therapeutics reports Q3 EPS (94c), consensus (79c)
- Kymera Therapeutics sees cash runway into 2H28
- Kymera Therapeutics assumed with a Buy at Guggenheim